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To generate a biobetter that has improved therapeutic 
activity, we constructed scFv libraries via random mu-
tagenesis of several residues of CDR-H3 and -L3 of 
hu4D5. The scFv clones were isolated from the phage 
display libraries by stringent panning, and their anti-
proliferative activity against HER2-positive cancer cells 
was evaluated as a primary selection criterion. Conse-
quently, we selected AH06 as a biobetter antibody that 
had a 7.2-fold increase in anti-proliferative activity (IC50: 
0.81 nM) against the gastric cancer cell line NCI-N87 
and a 7.4-fold increase in binding affinity (KD: 60 pM) to 
HER2 compared to hu4D5. The binding energy calcula-
tion and molecular modeling suggest that the substitu-
tion of residues of CDR-H3 to W98, F100c, A101 and 
L102 could stabilize binding of the antibody to HER2 
and there could be direct hydrophobic interactions be-
tween the aromatic ring of W98 and the aliphatic group 
of I613 within HER2 domain IV as well as the heavy and 
light chain hydrophobic interactions by residues F100c, 
A101 and L102 of CDR-H3. Therefore, we speculate that 
two such interactions were exerted by the residues W98 
and F100c. A101 and L102 may have a synergistic effect 
on the increase in the binding affinity to HER2. AH06 
specifically binds to domain IV of HER2, and it de-
creased the phosphorylation level of HER2 and AKT. 
Above all, it highly increased the overall level of p27 
compared to hu4D5 in the gastric cancer cell line NCI-
N82, suggesting that AH06 could potentially be a more 
efficient therapeutic agent than hu4D5. 1 
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HER2 is a member of the ErbB/HER (Human epidermal growth 
factor receptor) family, which consists of EGFR, HER2, HER3 
and HER4, and plays important roles in growth, differentiation 
and survival in cancer cells as well as in normal cells (Nicolas et 
al., 2008). In contrast to other HER family members, HER2 
does not require ligands for receptor-receptor interactions (Ni-
colas et al., 2008). In cancer cells, the HER2 protein can be 
expressed up to 100 times more than in normal cells (2 million 
versus 20,000 per cell) (Shepard et al., 1991). Such overex-
pression or amplification of HER2 promotes the formation of 
receptor homo- and heterodimers with other HER family mem-
bers, leading to uncontrolled cell proliferation and tumor growth 
(Mayumi and Michihiko, 2006). Therefore, HER2 has been 
investigated as a promising therapeutic target for cancer. Par-
ticularly, targeted therapy using anti-HER2 monoclonal antibod-
ies such as Herceptin (Trastuzumab, hu4D5, binds to domain 
IV), Kadcyla (Trastuzumab-maytansinoid, antibody-drug conju-
gate) and Perjeta (Pertuzumab, binds to domain II) has been 
used to treat HER2 positive cancers.  
Herceptin (trastuzumab, CAS Registry No. 180288-69-1) 
launched by Genentech in October 1998, is the humanized 
monoclonal antibody hu4D5. It binds to extracellular domain 
(ECD) IV of the HER2 receptor, subsequently inhibits its down-
stream PI3K-Akt signaling (Hudziak et al., 1989; Sliwkowski et 
al., 1999; Yakes et al., 2002) and induces cell cycle arrest via 
the induction of cyclin-dependent kinase inhibitor p27/kip1 and 
apoptosis (Carter et al., 1992) in metastatic HER2-positive 
breast and gastric cancer cells, which in turn inhibits HER2-
mediated tumor growth.  
A combination of Herceptin with chemotherapy has shown 
significant improvements in cancer treatment. Disease-free 
survivals at 3 years were 75.4% and 87.1% with chemotherapy 
alone and in combination with Herceptin, respectively, in pa-
tients with HER2-overexpressing metastatic breast cancer 
(Romond et al, 2005). However, despite its proven clinical ben-
efit, most patients who have an initial response to Herceptin 
develop resistance within one year of treatment initiation. 
Accordingly, the community needs to develop another anti-
HER2 antibody with improved efficacy. A popular strategy to 
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mutagenesis, and particularly, substitution of the residues at 
some positions of CDR-H and CDR-L would be considered. 
Based on this strategy, it was previously reported that the sub-
stitution of residues in the CDRs of hu4D5 influences antibody 
affinity (Gerstner et al., 2002). 
In the previous study, Gerstner et al. constructed phage-
displayed Fab libraries targeting 19 positions of hu4D5, includ-
ing R50(VH), W95(VH), Y100a(VH) and H91(VL), known to be 
important in binding to the HER2 molecule (Gerstner et al., 
2002; Kelly and O’Connell, 1993). The libraries consisted of five 
groups with randomized 5-7 residues. Through screening, the 
binding affinity of a single mutant D98(VH)W (KD 0.11 nM) was 
increased 3-fold compared to the parent antibody hu4D5, but its 
anti-cancer activity was not reported. The authors also sug-
gested that further improvement in binding affinity might be 
found using alternative methods of binding selection or target-
ing more variable positions (Gerstner et al., 2002). However, 
there have been no reports of success in screening variants 
superior to D98(VH)W in binding affinity and functional activity 
such as anti-cancer activity. 
The aims of our study were to investigate whether further 
modifications of an antibody that has already undergone affini-
ty-maturation could improve its binding affinity and subsequent 
efficacy and to develop a strategy for antibody improvement, 
using hu4D5 as a model system. Therefore, we generated 
random mutant libraries using an error-prone PCR method and 
degenerate random mutagenesis of VH/VL CDRs of hu4D5, and 
then the antibody variants with high affinity were isolated from 
the libraries using phage display. As a result, we successfully 
identified a variant with a 7.4-fold higher affinity and 7.2-fold 
greater antitumor activity compared to hu4D5. In addition, we 
speculate how the modifications in hu4D5 improve binding 
affinity using molecular modeling.  
 
MATERIALS AND METHODS   
 
Construction of scFv libraries  
Phage-displayed scFv (a single chain variable fragment) librar-
ies were constructed using a phagemid vector pCMTG (Oh et 
al., 2007) encoding the scFv-pIII fusion protein. The structure of 
the vector is schematically shown in Fig. 1A. The scFv, com-
prising a light variable chain, a linker and a heavy variable chain, 
was placed under the control of the lac promoter inducible by 
IPTG. The linker sequence was GGGGSGGGSGGSS.  
A “stop template” version of the scFv display vector generat-
ed using stop codon TGA was used as a PCR template to pre-
vent occurrence and enrichment of the template during the 
screening process.  
Libraries LN01 and LN02 randomized at four positions of the 
CDR-H3 (# 96, 97, 98 and 100) and at six positions of the 
CDR-H3 (# 98, 100, 100b, 100c, 101 and 102), respectively, 
were generated by degenerate PCR. The phage-displayed 
LN01 and LN02 libraries were mixed, and a panning procedure 
was carried out. To generate the LN03 library, which was ran-
domized at seven positions on CDR-L3, two sublibraries ran-
domizing four positions on each (#89, 90, 92, 93 and #93, 95, 
96, 97) were generated using degenerate PCR and combined, 
and then the panning procedure was performed. 
Degenerate PCR was performed using a Bio-Rad C1000 
thermal cycler according to the manufacturer’s instructions (Ex 
taq, Takara, Japan). The PCR conditions were as follows: dena-
turation, 95°C for 20 s; annealing, 57°C for 30 s; extension, 
72°C for 45 s; 27 cycles. The PCR scheme and primer sets 
used in this study are shown in Fig. 1 and Table 1, respectively. 
 
Selection of HER2-specific variants from scFv libraries 
The phagemid DNA libraries were introduced into E. coli XL1-
blue-MRF’ (Stratagene, USA) by electroporation (Sidhu et al., 
2000), and the transformants were infected with Ex12 helper 
phages (Back et al., 2002).  
To screen out HER2-specific antibodies from the libraries, 
MaxiSorp immunotubes (Nunc, 444202) were coated with hu-
man HER2-ECD (extracellular domain of ErbB2 or p185HER2, 
fused with Fc; R&D systems, USA). The libraries infected with 
Ex12 helper phage (IG therapy, Korea) were then used for 
panning according to the manufacturer’s instruction.  
Table 1. PCR primer sequences used for the library construction  
No. of 
Library PCR templates PCR purpose & methods 
No. of primer
and direction Primer sequences 
LN01 hu4D5 
(HFR4 S113 changed 
to stop codon TGA) 
Randomizing 4 positions of CDR-H3 
(96,97,98,100)  
Random Degenerate 
 1. Forward AATTgagctcGATATCCAGATGACCCAGAG 




(HFR4 S113 changed 
to stop codon TGA) 
Randomizing 6 positions of 
CDR-H3 
(98, 100, 100b, 100c, 101, 102)
Random Degenerate 
 1. Forward AATTgagctcGATATCCAGATGACCCAGAG 




(LFR3 C88 changed 
to stop codon TGA) 
Two sub-libraries : each randomizing 
4 positions of CDR-L3 
(89,90,92,93 and 93, 95, 96, 97) 
Random Degenerate 
 4-1. Forward GACTTCGCTACGTACTACTGCNNKNNKcacNNK 
NNKactcctccgacaTTCGGACAAGGCAC 
 4-2. Forward GACTTCGCTACGTACTACTGCcaacagcactacNNK 
actNNKNNKNNKTTCGGACAAGGCAC 
 5. Reverse AATTGCGCGCtactcacggtc 
*CDR, complementarity-determining region; FR, fram 
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The stringency of panning was controlled in a washing step 
and the plates were washed up to 20 times with TBS-T. After 
washing, 1.0-1.5 M ammonium thiocyanate was treated for 10 
min, followed by washing with TBS-T (Macdonald et al., 1998; 
Wang et al., 2000). 
 
Screening and relative ELISA  
After three to five panning procedures, screening ELISA using 
soluble scFv-pIII fusion molecules prepared from E. coli was 
performed as described previously (Song et al., 2009). 
In the screening ELISA, human HER2-ECD or human IgG 
(Sigma) and anti-pIII antibodies (MoBiTec, PSKAN3) were used 
as the coating antigen and detecting antibody, respectively. 
Consequently, we selected clones expressing phage-displayed 
scFv that bound to antigen-coated plates but not to IgG-coated 
plates.  
To assess the relative binding of the soluble scFv fragment 
expressed in E. coli, an ELISA was performed with thiocyanate 
solution. After scFv incubation, 1 M ammonium thiocyanate 
buffer was treated for 15 min at room temperature, followed by 
a washing step. The remaining steps were conducted as de-
scribed (Song et al., 2009). 
Phagemids extracted from the selected clones were ana-
lyzed by DNA sequencing, and then CDR were identified using 
NCBI IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/).  
 
Cloning, transient expression and purification of the  
isolated variants  
The mammalian expression vector systems pOptiVEC (for 
heavy chain expression, Invitrogen, USA) and pcDNA3.3 (for 
light chain expression, Invitrogen, USA) were used to express 
the full-length IgG1 antibody. FreeStyle CHO-S cells (Invitrogen, 
USA) were transfected with the expression vector containing 
the antibody gene according to the manufacturer’s protocol. 
Five days after transfection, the culture media were harvested 
and the IgG form of the antibody variant was purified using 
Mabselect (GE Healthcare, UK).  
 
Inhibitory activity of cancer cell proliferation in vitro 
The HER2-positive breast cancer cell line SK-BR-3 (HTB-30, 
ATCC) and the gastric cancer cell line NCI-N87 (CRL-5822, 
ATCC) were purchased from ATCC and maintained in McCoy’s 
5a (Gibco BRL, USA) and RPMI-1640 (Gibco BRL, USA), re-
spectively. The cells were seeded at a concentration of 7.5 × 
103 cells/well, cultured at 37°C with 5% CO2 overnight, and 
treated with the serially diluted antibodies the next day. After 6 
days of treatment, viable cells were counted by a WST-8 cell 
proliferation assay (Japan), as described previously (Gong et 
al., 2004). 
 
SPR (surface plasmon resonance) analysis  
We used a surface plasmon resonance biosensor (BIAcore™-
2000) to detect antibodies against HER2-ECD. After immobiliz-
ing HER2-ECD molecules onto the surface of M5 sensor chips 
(GE Healthcare, USA), as described previously (Johnsson et al., 
1991), at a level of approximately 90-130 response units, serial-
ly diluted antibodies were injected with increasing concentra-
tions (from 0.032 nM, 0.16 nM, 0.8 nM, 4 nM, 20 nM to 100 nM) 
at a flow rate of 10 μl/min for 5 min, followed by injection of a 
running buffer for 30 min to monitor dissociation. The equilibri-
um dissociation constant KD of the surface plasmon resonance 
was calculated as koff/kon. 
 
Domain specificity analysis of the isolated variants to 
HER2-ECD antigen (indirect ELISA)  
To determine the HER2 domain specificity of isolated variants, 
an ELISA was performed with recombinant ∆HER2-ECD, a 
partially deleted form of domain IV consisting of 562 amino 
acids from residue 22 to residue 584 of HER2 (Genentech 
Patent US6949245, 2005), fused with Fc or HER2-ECD fused 
Table 2. Deduced sequences, anti-cancer activity and binding kinetics of representative variants (as IgG format) from each library at 25°C. 
Residues were numbered according to Kabat and colleagues.  






activity : ratio of 








ratio of KD 
(hu4D5) / 
(variant) SK-BR-3 NCI-N87 
- hu4D5 SASFLYS QQHYTTPPT WGGDGFYAMDY 1.0 (0.9-4.5nM)
1.0 
(5.88nM) 2.4 1.2 0.48 1.0 
- D98W -------- --------- ---W------- 0.89 0.48 4.9 0.6 0.11 4.3 
LN01 AH12 ------- --------- -H-V-M----- 0.84 ND 2.5 2.8 1.12 0.4 





------- --------- --------FAL 1.16 5.96 3.0 0.5 0.15 3.1 
** AH16 ------- --------- -NAK---SFVH 1.14 1.67 5.1 0.7 0.15 3.1 
LN03 AL07 ------- ----I-NI- ----------- 0.87 ND 2.3 1.8 0.79 0.6 
C02 A058 ------- ----Q--AS ---W----FAL 1.02 2.79 2.2 2.3 1.05 0.5 
*To evaluate the effect of position 98 in CDR-H3, W98 in CDR-H3 of AH06 was substituted with D98. ** Direct engraftment of changed resi-
dues of CDR-H3 from the LN01 and LN02 libraries. CDR, complementarity-determining region; FR, framework; dashes indicate sequences 
identical to that of hu4D5. Values for kon and koff are measured at 25°C by SPR on BIAcore. The relative affinity, reported as KD (parent)/KD 
(variant) indicates the fold increase in the binding affinity versus the parental antibody hu4D5. ND: not-determined. 
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with Fc (R&D system, USA) as coating antigens. MaxiSorp 96-
well microtiter plates (Corning, USA) were coated with 0.5 
μg/ml of recombinant ∆HER2-ECD fused with Fc or HER2-
ECD fused with Fc (R&D system, USA).  
After an overnight incubation at 4°C, the plates were washed 
with TBS-T and blocked with 5% nonfat milk. Then, the plates 
were treated with the isolated antibody variants and incubated 
with HRP-conjugated anti-human kappa chain (Sigma, USA). 
An ELISA analysis was performed as described previously 
(Yoon et al., 2006). 
 
Cross-reactivity analysis of the isolated antibody to other 
receptor tyrosine kinases (Indirect ELISA)  
To analyze the cross-reactivity of the antibodies to receptor 
tyrosine kinases other than HER2, MaxiSorp 96-well microtiter 
plates were coated with 1 μg/ml of Fc-fused ECD of PDGFRβ, 
VEGFR2, IGF-IR, FGFR3 (IIIc), EGFR, HER3 or HER4 (R&D 
systems, USA) or 2 μg/ml of HGFR/c-Met ECD-Fc (R&D sys-
tems, USA). After an overnight incubation at 4°C, the plates 
were incubated with 30 nM of the isolated antibody variants at 
37°C for 2 h.  
After washing with TBS-T, the plates were treated with anti-
goat IgG-peroxidase antibody (Sigma, A5420) or anti-mouse 
IgG-peroxidase antibody (Sigma, A9044) at 37°C for 1 h. ELISA 
analysis was performed as described previously (Yoon et al., 
2006). 
 
Inhibitory effect of the isolated variants to HER2 signaling 
(Immunoblot)  
The NCI-N87 cells were seeded at a concentration of 2 × 105 
cells/ml into a 100-mm cell culture dish, treated with 10 μg/ml of 
antibodies for 16 h to analyze pAkt and 72 h to analysis p27, 
and lysed by adding RIPA buffer (1.0% NP-40, 0.5% deoxy-
cholic acid, 0.1% SDS, 50 mM Tris-HCl, pH 8.0) with 1 mM 
EDTA, 1 mM PMSF, protease inhibitor cocktail (Thermo, USA) 
and phosphatase inhibitor cocktail (Thermo, USA). Western 
blot analysis was performed as described previously (O'Brien et 
al., 2010). 
 
Computing the stability and analyzing antibody-antigen 
interaction 
To analyze the molecular interactions between the antibody 
and HER2 (P04626, UniProtKB), we obtained the structural 
information for HER2 and hu4D5 from the PDB (code: 1N8Z; 
web site: http://www.rcsb.org/pdb/home/home.do). The effects 
of mutations in the antibody variable regions on stability, force 
field and charges were estimated using CHARMm module and 
Momany-Rone, respectively (Discovery Studio 3.5, Accelrys 
Inc., USA, http://accelrys.com/). Data on intraprotein interac-
tions were obtained from the Protein Interactions Calculator 
(http://pic.mbu.iisc.ernet.in/), and the binding energy between 
the antibody and HER2 molecule was calculated by equation 1 
below. 
All the experiments were carried out on a 3.40 GHz Intel 
Core i7 Quard-Core processor. Molecular modeling was per-
formed using the Macromolecules modules on Discovery Stu-
dio 3.5 (Accelrys Inc.), and CHARMm (ver. 36.2) was used for 
energy minimization. 
 
Equation 1. Binding energy of antibody and antigen HER2 
∆G HER2:VH/VL binding energy = ∆G HER2/VH/VL energy – (∆G HER2 energy + ∆G 
VH/VL energy) 
Fig. 1. Construction of pCMTG scFv expression vector (A) and schematic representation of randomized libraries LN01 (B), LN02 (C) and
LN03 (D). Thin black arrows indicate the primers to construct each randomized library. The PCR template for LN01 and LN02 was a modified
version that contained a TGA stop codon introduced at the S113 residue. For the PCR template for LN03, a TGA stop codon was introduced at
the C88 residue. X denotes the replacement of a codon with the degenerate codon NNS. CDR residues are numbered according to Kabat
and Wu. (1991). 
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Construction of variants scFv libraries  
Because the parent antibody hu4D5 had high affinity (KD value 
of 0.54 nM, Table 2), it was difficult to identify an antibody with 
improved affinity using a general panning method. We were 
also concerned that the tight-binding "contaminant (parent or 
template antibody, hu4D5)" scFv might be dominantly selected 
because the parent antibody hu4D5 is an extremely tight-
binding antibody. Thus, the template for each library was a 
modified version of phagemid, with a stop codon (TGA) intro-
duced at an upstream or downstream position where the amino 
acid was to be mutated by the overlapping PCR method. A 
different position introducing a stop codon for each library is as 
follows: the S113 position of HFR4 in CDR-H3 for the LN01 and 
LN02 libraries and the C88 position in CDR-L3 for the LN03 
library (Fig. 1). 
To minimize the library size and number of constructions, we 
primarily excluded CDR-H1, CDR-L1, and CDR-H2, which 
consisted of 5, 10, 17 and 7 residues, respectively. However, 
the strategy for site-directed random mutagenesis of all the 
CDR residues, including CDR-H3 (Kabat No. #95~102, 11 amino 
acid residues, W95G96G97D98G99F100 Y100aA100bM100cD101Y102) and 
CDR-L3 (Kabat No. #89~97, 9 amino acid residues, Q89Q90H91 
Y92T93T94P95P96T97), is practically impossible because the theo-
retical diversity of each library is 2 x 1014 and 5 x 1011, respec-
tively, which is too large to construct the libraries. 
To design a library with a suitable size for efficient screening, 
the CDR-L3 H91, CDR-H3 W95 and CDR-H3 Y100a positions 
(Gerstner et al., 2002), previously reported to be the most criti-
Fig. 2. Candidate screening flow scheme. ELISA units and anti-proliferative activity against tumor cells were considered in selecting variants.
The variants whose SE and RE values were 5-fold higher than those of the negative blank were selected. Then, further selection proceeded
based on RA as indicated. SE, Screening ELISA unit of OD450; RE, Relative ELISA unit of OD450; RA (Relative activity), a ratio of IC50 of parent
hu4D5 to the variant in anti-proliferative activity against breast tumor SK-BR-3 or gastric tumor NCI-N87 cells. 
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cal to antigen binding key residues, were excluded from ran-
domization. G99 (90% or 100%) in CDR-H3 and T94 (45%) in 
CDR-L3 were conserved at frequencies higher than 45% after 
screenings from the random mutagenesis library and were also 
excluded from randomization. Although F100 in CDR-H3 was 
conserved with a frequency 52% (Gerstner et al., 2002), the 
F100 position, shown to play a role in the antigen-antibody 
interface (Kelley et al., 1993), was designated as a target site 
for randomized library construction.  
In conclusion, a total of 5 residues consisting of key residues 
(CDR-L3 H91, CDR-H3 W95 and CDR-H3 Y100a) and relative-
ly invariant residues (CDR-H3 G99 and CDR3 T94) were ex-
cluded from randomization in the library construction. Libraries 
targeting CDR-H3 and CDR-L3, with the exception of the 5 
residues described above, were constructed using an NNK 
codon (N = A, G, T or C; K = G or T) in 3 divided subgroups. 
CDR-H3 and CDR-L3 targeting the LN01, LN02 and LN03 
libraries were constructed according to the mutagenesis strate-
gy, and the diversities of each library were 9.7 × 107, 1.5 × 108 
and 3.7 × 108, respectively. 
 
Selection of HER2-specific variants from scFv libraries  
After library construction, we screened variants in accordance 
with the strategy described in Fig. 2. High-stringency screening 
to select an antibody with a higher affinity than the parent anti-
body hu4D5 was performed as follows. First, washing was 
carried out for up to 44 hours to select an antibody exhibiting an 
enhanced off-rate (Chen et al., 1999). Second, a pre-elution 
was performed with 0.1 M glycine (pH 2.2) before the final elu-
tion (Chen et al., 1999). Third, weakly bound antibodies were 
removed by treating with ammonium thiocyanate before elution 
(Macdonald et al., 1998; Wang et al., 2000). The washing step 
was performed with 0.1 M glycine (pH 2.2) and 1 M ammonium 
thiocyanate in any order during three to five rounds of panning.  
Finally, the antibodies with high affinity were enriched during 
successive rounds of panning by decreasing the concentration 
of HER2 ECD-Fc from 2.0 to 0.1 μg/ml. If the number of colo-
nies from a negative antigen (human IgG or BSA) after panning 
was less than 1% of that of HER2, we proceeded with the 
screening.  
Because the primary purpose of this study was to improve 
the biological activity of the antibody, the ratio or fold increase of 
the variants to hu4D5 in anti-proliferative activity was calculated 
as IC50 of hu4D5 / IC50 of variant. We planned to select the 
variants with a ratio of 1 or more in their activity against SK-BR-
3 cells as a candidate for a biobetter antibody. 
All 5, 9 and 13 variants derived from LN01, LN02 and LN03, 
respectively, failed to meet the criterion, except the variant 
AH06 from LN02 (a ratio of 1.3 for SK-BR-3 cells). Because the 
substitution occurred in either CDR-H3 or L3, we further inves-
tigated whether a combination of CDR substitutions could in-
crease the anti-proliferative activity.  
To generate combinatorial variants by shuffling the variants 
from LN03 with randomized VL and the variants from LN01 or 
LN02 with randomized VH, we selected 3, 8, and 8 variants 
whose activity ratio for SK-BR-3 cells was more than 0.7, 0.8 
and 0.7 from LN01, LN02 and LN03, respectively.  
Two series of the combinatorial expression of heavy and light 
chain variants, C01 (CDR-H3 variants from LN01 and CDR-L3 
variants from LN03) and C02 (CDR-H3 variants from LN02 and 
CDR-L3 variants from LN03) were implemented by transient 
expression in CHO-S cells (Fig. 2).  
In C01, a total of 24 variants by the combination of three 
CDR-H3 variants from LN01 and eight CDR-L3 variants from 
LN03 were expressed transiently in CHO-S cells. Twenty-three 
variants were purified and their anti-proliferative activity against 
SK-BR-3 cells was assessed. However, there were no variants 
with an activity ratio of 1.0 or more.  
In C02, a total of 64 variants of the combination of eight 
CDR-H3 variants from LN02 and eight CDR-L3 variants from 
LN03 were expressed transiently in CHO-S cells. As a result of 
measuring the anti-proliferative activity of 58 IgGs selected from 
C02 against SK-BR-3 cells, there were 15 variants with an 
activity ratio of 1.0 or more. There were no variants with signifi-
cantly enhanced anti-cancer activity compared with AH06 de-
rived from LN02.  
Several variants, such as AH06, selected from a total of 109 
variants, were further tested for anti-cancer activity against the 
Fig. 3. Inhibitory effects of hu4D5 variants in 
NCI-N87 cell proliferation. Cells were treated 
with the indicated concentrations of variants for 6 
days. Cell viability is expressed as a percentage 
relative to the untreated control. Data represent 
the average ± SD of three experiments. The cell 
growth inhibitory activity against NCI-N87 of 
AH06 (IC50 0.12 μg/ml = 0.81 nM) was increased 
7.2 times compared with the parental antibody 
hu4D5. 
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HER2-positive gastric cancer cell line NCI-N87 and binding 
affinity using BiacoreTM. 
 
Inhibitory effects on cell proliferation and the binding  
affinity of AH06 
The variant AH06, which had a 7.2-fold enhanced anti-
proliferative activity against NCI-N87 cells (Fig. 3) in compari-
son to hu4D5, was derived from the library LN02, has an 
unchanged light chain and a substituted heavy chain with 
changes in D98W, M100cF, D101A, and Y102L of CDR-H3. 
AH06 also showed substantially enhanced binding affinity. 
The affinity of AH06 was 7.4-fold and 2.4-fold higher com-
pared to those of the parent hu4D5 and D98W, the previously 
reported variant (Gerstner et al., 2002), respectively (Table 2 
and Fig. 4).  
Because it has been reported that D98W, which contains the 
substitution of Glu for Trp at position 98 in CDR-H3, has a bind-
ing affinity approximately 3 times higher than that of hu4D5 
(Gerstner et al., 2002), a modified version of AH06 (AH06 
W98D), in which Trp was substituted with Glu at position 98, 
was constructed to evaluate whether the mutation has any 
impact.  
The binding affinity of AH06 W98D was also 3.1 times higher 
than that of hu4D5, suggesting that the change in the sequence 
of "F100c A101 L102" contributes to the improvement in its 
binding affinity of 3.1-fold for the HER2-ECD molecule. The 
binding affinity of D98W was improved 4.3-fold, whereas AH06 
showed a 7.4-fold higher binding affinity than hu4D5 (Table 2; 
Fig. 4), which suggests that W98 and the F100c A101 L102 
sequence synergistically improve the binding affinity. 
 
Domain specificity against the HER2 molecule and  
cross-reactivity to other receptor tyrosine kinases of the 
AH06 
The binding ELISA showed that the variant AH06 was capable 
of binding to domain IV of the HER2 antigen, similar to hu4D5 
(Fig. 5A). In addition, AH06 did not bind to any other RTKs 
(EGFR, HER2, HER3, HER4, PDGFRβ, VEGFR2, IGF1R, 
FGFR3 and HGFR) (Figs. 5B and 5C), indicating that it is highly 
specific to the HER2 antigen.  
 
Effects of the AH06 on downstream signaling of HER2  
To investigate the inhibitory mechanism of AH06 against HER2 
signaling in the gastric cancer cell line NCI-N87, the protein 
levels, including HER2, phosphorylated HER2 (pHER2), Akt, 
phosphorylated Akt (pAkt) and p27, were examined by western 
blot analysis (Fig. 6). Phosphorylation of HER2 and AKT were 
inhibited without a change in protein expression of HER2 and 
Akt by treatment of hu4D5 as well as AH06.  
On the other hand, the expression level of the cyclin-
dependent kinase inhibitor p27 was greatly increased when 
cells were treated with AH06. These results suggest that the 
AH06 antibody inhibits activation of the PI3K-Akt signaling 
pathways via HER2 and induces cell death by increasing the 
expression of p27. Thus, cell-context dependent induction of 
p27 might contribute to cellular susceptibility to AH06. 
 
Computing stability and analyzing antibody-antigen  
interactions 
To analyze the binding modes and binding energies of the 4 
changed residues (W98, F100c, A101 and L102) of AH06 to its 
antigen HER2 (P04626, UniProtKB), we used molecular model-
ing methodology and Equation 1. AH06 had a higher binding 
affinity for HER2 as well as lower binding energy compared to 
hu4D5 (Table 3), suggesting that AH06 could bind to HER2 
more stably than did hu4D5. 
Next, we investigated which of the 4 residues (W98, F100c, 
A101 and L102) of AH06 contributed to the increase in binding 
affinity and binding energy. The substitution with W at position 
98 increased the binding affinity and decreased the binding 
energy, suggesting that W98 plays a significant role in binding 
to HER2. 
The binding affinity of “modified AH06” was approximately 3-
fold higher than that of hu4D5. However, unexpectedly there 
was no significant improvement in the binding energy of “modi-
fied AH06” compared to that of hu4D5.  
Fig. 4. SPR binding analysis of isolated variants to immobilized human HER2-ECD. Antibody variants were injected at six different concentra-
tions, 0.032 nM, 0.16 nM, 0.8 nM, 4 nM, 20 nM and 100 nM, over a surface on which 100 RU of HER2-ECD had been coupled. The parame-
ters solved for each run are shown in Table 2. AH06 has a 7.4-fold improved affinity, reaching a KD of 60 pM, compared to that of the parent,
hu4D5 (KD 0.48 nM). The χ2 values of the fitted curves were < 1. 
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Analysis of the binding affinity and binding energy of the 
CDR-H3 variants indicates that the 3 residues F100c, A101 and 
L102 of AH06 can enhance the binding affinity to HER2 (by 
additional hydrophobic interactions) approximately 3-fold; how-
ever, W98 of CDR-H3 has the greatest impact. These results 
suggested that the residues W98, F100c, A101 and L102 of 
CDR-H3 of AH06 exert synergistic effects on the binding affinity 
to HER2 and the binding energy.  
To elucidate our experimental data, we simulated and ana-
lyzed the binding modes of hu4D5 and AH06 to HER2 using 
molecular modeling. The residues F100c, A101 and L102 of 
CDR-H3 of AH06 were located at the VH-VL interface. Because 
these 3 residues were located several Ås away from the HER2 
residues (Fig. 7A), it is unlikely that the residues directly interact 
with HER2 antigen. 
It was demonstrated that there could be a direct hydrophobic 
interaction between the aromatic ring group of the tryptophan 
residue (W98) of AH06 and the aliphatic group of the isoleucine 
(I613) residue located in domain IV of HER2 as well as the 
heavy and light chain hydrophobic interactions between the 
phenyl ring of F100c in CDR-H3 and the hydrophobic groups 
that is consist of Y36, P44 and F98 located in VL (Fig. 7B). On 
the other hand, there was no significant interaction between 
residue D98 of hu4D5 and the isoleucine (I613) residue in the 
aliphatic group located in domain IV of HER2 (Figs. 7C and 7D). 














Fig. 5. ELISA assay. (A) Domain specificity of the antibody against HER2. Cross-reactivity of the antibody to the HER family (B) and receptor
tyrosine kinase family (C). Antigens were immobilized in each well and incubated with various concentrations of antibodies. Bound antibody
was detected using anti-human IgG conjugated to HRP. AH06 specifically bound to HER2, particularly its domain IV. 
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between the W98 and F100c and A101 and L102 could have a 




Antibody affinity maturation by phage display is a highly efficient 
way of developing therapeutic antibodies (Lowe et al., 2012). 
Gerstner et al. chose 19 surface-exposed residues, including 
12 residues of CDR-H and 7 residues of CDR-L, known to be 
located in the areas directly contacting HER2, and constructed 
randomized Fab libraries targeting these residues. They chose 
and combined 5-7 residues, including 2-4 residues from CDR-H 
and 1-3 residues from CDR-L per library and randomized all 
these residues at the same time (Gerstner et al., 2002). 
In contrast to previous studies, we choose 6 residues at posi-
tions #98, 100, 100b, 100c, 101 and 102 of CDR-H3 and ran-
domized those 6 residues simultaneously. In addition, because 
it has been reported that binding affinity can be increased by a 
combination of mutations isolated from separate libraries 
(Schier et al., 1996), we randomized the residues within either 
CDR-H3 or CDR-L3, panned each library, and selected the 
variants based on their anti-cancer activities. Then, the selected 
variants were cloned into the expression vectors pOptiVEC (for 
heavy chain expression) or pcDNA3.3 (for light chain expres-
sion). An additional diverse antibody repertoire was achieved 
by a combination of heavy and light chains, and the resulting 
IgG antibodies with substituted residues in both the heavy and 
light chains were expressed in CHO-S cells and finally evaluat-
ed on their anti-cancer activity (step-by-step screening scheme, 
Fig. 2). 
We used a step-by-step rather than one-step strategy to effi-
ciently randomize both CDR-H and CDR-L without difficulty in 
determining the position and the number of residues for ran-
domization. Such a substitution of both CDR-H and CDR-L was 
expected to further improve the binding affinity as well as the 
functional activity of the antibody.  
Contrary to our expectations, the HER2-binding affinity of 
A058, which was substituted with W98, F100c, A101, and L102 
in CDR-H3 (identical to AH06) and had 3 residues substituted 
with Q93, A96 and S97 in CDR-L3, was reduced to half that of 
hu4D5, although its anti-tumor activity against SK-BR-3 was 
similar to that of hu4D5. Therefore, the data suggest that the 
modification of CDR-L3 may be unable to largely contribute to 
the increase in HER2-binding affinity.  
Nevertheless, AH06, with its 7.4-fold increase in binding affin-
ity, was generated from LN02, which randomized 6 residues at 
positions #98, 100, 100b, 100c, 101 and 102 of CDR-H3 at a 
time. Consistent with our conclusion, it has been reported that 
the binding affinity of antibodies is increased by the substitu-
tions of CDR-H3 residues, such as the 100c, 101 and 102 posi-
tions (Phumyen et al., 2012; Rajpal et al., 2005).  
In addition, as Gerstner et al. (2002) mentioned, a role of 
W98 of CDR-H3 in HER2 binding is unclear. Here we provide a 
possible explanation for that using modeling analysis regarding 
improvement of binding affinity of AH06. The simulation model-
ing suggested direct hydrophobic interactions between the 
aromatic ring group of tryptophan residue (W98) of AH06 and 
the aliphatic group of isoleucine (I613) residue located in the 
domain IV of HER2, and also between the phenyl ring of F100c 
in CDR-H3 and the hydrophobic groups that consist of Y36, 
P44 and F98 located in VL (Fig.7). 
We speculate that the hydrophobic interactions between the 
heavy and light chain within AH06, induced by the substitution 
of the residues F100c, A101 and L102 of CDR-H3, could help 
increase the binding affinity, though not as strongly as W98. 
Our speculation is supported by studies reporting that residues 
that do not interact or contact antigen directly influence the 
interaction between the heavy and light chain, and thus in-
crease binding affinity (Chatellier et al., 1996; Hawkins et al., 
1993). 
Fig. 6. Effects of the parent antibody hu4D5 and AH06 on HER2
signaling. Protein levels of HER2, pHER2, Akt, pAkt and p27 were
assessed in NCI-N87 gastric cancer cells after antibody treatment
for 16 h to analyze pHER2, HER2 and pAkt and 72 h to analyze p27
by Western blot. The β-actin was used as a loading control. 
Table 3. Binding energies and affinities of AH06 and hu4D5. AH06 had a higher binding affinity for HER2 as well as a lower binding energy, 
compared to hu4D5. 
A. Binding energy ∆G HER2/VH/VL ∆G HER2 ∆G VH/VL ∆GHER2:VH/VL 
hu4D5 -19716.1 -12050.6 -7374.3 -291.2 
Modified AH06 -19394.5 -12050.5 -7052.0 -292.0 
AH06 -19432.8 -12050.7 -7065.2 -316.9 
B. Binding affinity (Biacore)     
Antibody Ka (1/Ms) Kd (1/s) KD (M) ∆G(kcal/mol) 
hu4D5 2.4 x 105 1.2 x 10-4 0.48 x 10-9 -291.2 
Modified AH06 3.0 x 105 0.5 x 10-4 0.15 x 10-9 -292.0 
AH06 7.7 x 105 0.5 x 10-4 0.06 x 10-9 -316.9 
     
hu4D5, CDR-H3 D98, M100c, D101, Y102; modified AH06, CDR-H3 D98, F100c, A101, L102; AH06, CDR-H3 W98, F100c, A101, L102 
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 Fig. 7. Molecular interaction models of AH06 and 
hu4D5 complex with HER2. (A) A distance between 
three residues, F100c, A101 and L102 of modified 
AH06 (blue circle) and HER2 molecule (green). The 
residues F100c, A101 and L102 of CDR-H3 of AH06 
were located in the region of VH-VL interface. The VH 
domain and VL domain are colored with red and blue, 
respectively. (B) Molecular interactions between VH 
and VL. The VH domain and VL domain are colored 
with pink and light blue. The residues F100c, A101 
and L102 of CDR-H3 and Y36, P44 and F98 of VL 
were located in the region of VH-VL interface. It was 
simulated that there could be a direct hydrophobic 
interaction between the phenyl ring of F100c in CDR-
H3 and the hydrophobic groups that is consist of Y36, 
P44 and F98 located in VL. (C) Ribbon model : The 
mutated region of variants is presented as a red 
square. (D) Surface model : The mutated region of 
variants is presented as a yellow square. (brown : 
hydrophobic, blue : hydrophilic). It was simulated that 
there could be a direct hydrophobic interaction be-
tween the aromatic ring group of tryptophan residue 
(W98) of AH06 and the aliphatic group of isoleucine 
(I613) residue located in the domain IV of HER2 as 
well as the heavy and light chain hydrophobic interac-
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Since Herceptin has been widely and mainly used in breast 
cancer treatment, we screened and evaluated the anti-cancer 
proliferative activity of the antibody variants in breast cancer cell 
line SK-BR-3 first, and then in gastric cancer cell line NCI-N87. 
However, it would have been possible to get better clones, if the 
antibody variants had been screened in NCI-N87 first or co-
screened in NCI-N87 and SK-BR-3 cells.  
Although AH06 with the strongest binding affinity showed the 
most effective anti-proliferative activity, our data (Table 2) did 
not show a direct correlation between antigen binding affinity of 
antibody and its biological activity. However, it is consistent with 
the report that the anti-proliferative activity of humAb4D5 vari-
ants against HER2 overexpressing SK-BR-3 cells is not simply 
correlated with their binding affinity for the HER2 (Carter et al., 
1992): the variant humAb4D5-3 with a binding affinity similar to 
that of humAb4D5-2 had a significantly enhanced anti-
proliferative activity compared to humAb4D5-2.  
AH06 showed an 7.2-fold enhanced anti-proliferative activity 
against NCI-N87 gastric cancer cells compared to hu4D5, alt-
hough it did not greatly enhance the activity against SK-BR-3 
breast cancer cells. HER2 gene amplification is higher in NCI-
N87 compared with SK-BR-3: the HER2 amplification ratios 
relative to CEP17 were 8.4 and 4.9 in NCI-N87 and SK-BR-3 
cells, respectively (Kim et al., 2008), and receptor/ligand avidity 
generally increases with the density of the receptor on cell sur-
face (Lesley et al., 2000). Therefore, AH06 may be able to 
more efficiently bind to and inhibit NCI-N87 cells having a high-
er density of HER2 than SK-BR-3 cells.  
In addition, its anti-cancer activity of AH06 was HER2-specific, 
and its effect was confirmed at the level of signal transduction, 
indicating that AH06 is distinctly superior to hu4D5. Therefore, 
we suggest that AH06 could be clinically developed as a thera-
peutic anti-cancer antibody over hu4D5 (Herceptin). 
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